Evidence map›Paper›PMID 42154186›Full record

ArticleEJNMMI radiopharmacy and chemistry2026

Automated GMP production and long-term experience in radiosynthesis of the SV2A tracer [

Saara Wahlroos, Anna Krzyczmonik, Semi Helin, Johan Rajander, Olof Solin, Anna K Kirjavainen

Abstract read
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Saara Wahlroos *Radiopharmaceutical Chemistry Laboratory, Turku PET Centre, University of Turku, Turku, Finland. saara.wahlroos@utu.fi.ORCID http://orcid.org/0000-0003-0952-0945
Anna Krzyczmonik *Radiopharmaceutical Chemistry Laboratory, Turku PET Centre, University of Turku, Turku, Finland.ORCID http://orcid.org/0000-0003-4702-9225
Semi HelinRadiopharmaceutical Chemistry Laboratory, Turku PET Centre, University of Turku, Turku, Finland.ORCID http://orcid.org/0000-0002-9405-7301
Johan RajanderAccelerator Laboratory, Turku PET Centre, Åbo Akademi University, Turku, Finland.ORCID http://orcid.org/0000-0003-3591-0963
Olof Solin *Radiopharmaceutical Chemistry Laboratory, Turku PET Centre, University of Turku, Turku, Finland.ORCID http://orcid.org/0000-0003-1026-4029
Anna K Kirjavainen *Radiopharmaceutical Chemistry Laboratory, Turku PET Centre, University of Turku, Turku, Finland. anna.k.kirjavainen@utu.fi.ORCID http://orcid.org/0000-0003-3981-2973

Funding

Academy of Finland 334310Svenska Kulturfonden 151484Turun Yliopistollinen Keskussairaala 11133Turun Yliopistollinen Keskussairaala 13250
6 · The paper itself

Abstract

backgroundPositron emission tomography (PET) is a non-invasive imaging technique that enables the quantification of specific biological and pharmacological processes in vivo. PET can be used to investigate synaptic density by targeting synaptic vesicle glycoprotein 2A (SV2A), and can measure brain levels of SV2A in patients with epilepsy and other neurologic, neurodegenerative, or psychiatric conditions that involve SV2A. The well-known radiotracer [

results[

conclusionsThe developed method enables robust [

Indexed as

[11C]UCB-JAutomationCarbon-11GMPPET radiochemistryradioHPLCRadiopharmaceuticalSPESuzuki–Miyaura cross-couplingSV2A

Identifiers

PMID42154186
PMCPMC13357469

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.